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Summary.-We have studied the repair of X-ray-induced, potentially lethal damage
(PLD) in 9 human tumour lines derived from tumours of varying radiocurability.
Cells derived from 3 tumours considered non-radiocurable (1 osteosarcoma, 2
melanoma) repaired significantly more X-ray PLD than cells from 3 tumours con-
sidered radiocurable (2 breast, 1 neuroblastoma). The remaining tumour lines were
intermediate in their ability for repair, and included cells from another osteosarcoma,
a hypernephroma and a glioblastoma. We conclude that the repair of X-ray PLD
may be an important cellular determinant of clinical radiocurability.
TUMOUR RADIOCURABILITY (local con-
trol) has been thought to depend on
variables such as hypoxia, host factors,
tumour size and scheduling and delivery
of ionizing radiation. These factors have
received wide attention in clinical human
data analysis and have been extensively
studied in animal tumour systems. The
cellular and molecular repair processes
that may contribute to local control of
human neoplasia are less understood.
This results both from the ethical prob-
lems involved in human experimentation
and the relatively slow evolution of in
vitro techniques for the study of human
tissue.
Plateau-phase cultures have been pro-
posed as useful in vitro models, with
certain characteristics of in vivo tumours,
particularly as these cultures contain a
population of non-cycling cells (Hahn &
Little, 1972; Little 1969). When density-
inhibited plateau-phase cultures are treat-
ed with X-rays and subculture of the cells
at low density is delayed, an enhancement
in survival occurs. This phenomenon has
been referred to as reflecting the recovery
from potentially lethal X-ray damage
(PLDR) and is analogous to liquid-holding
recovery in bacteria (Hahn & Little, 1972;
Little, 1969). PLDR has been described
in animal ascites and solid tumours, as
well as established animal tumour lines
(Little et al., 1973; Shipley et al., 1975). We
have previously examined PLDR in
diploid fibroblasts from normal indivi-
duals and patients with diseases which
demonstrate defects in DNA repair
(xeroderma pigmentosum. XP, ataxia
telangiectasia, AT) and concluded that
PLDR reflected the activity of a molecu-
lar repair process (Weichselbaum et al.,
1978). On this basis of the results of
another study, we further postulated that
the clinical incurability of a human
osteosarcoma might be due to efficient
PLDR (Weichselbaum et al., 1977b).
The enhanced survival that occurs when
a radiation dose is split with an interval
of several hours between fractions has
been interpreted as due to the repair of
sublethal damage (SLDR) induced by the
first dose in cells that survive this dose
(Elkind & Sutton, 1959). The ability ofthe
cells in a tumour to accumulate and repair
sublethal damage has been postulated to
be a major cellular determinant in radio-
curability; the capacity for SLDR hasPLD REPAIR IN HUMAN TUMOUR CELLS
been thought to be reflected by the
extrapolation number (n), the back extra-
polate of the slope of radiation survival
curve for these cells plotted semi-
logarithmically.
A major factor in the failure of X-rays
to sterilize a malignant tumour may be the
ability of the cells from that tumour to
recover from X-ray damage. We have
measured the repair of PLDR and SLDR
following X-rays in human tumour lines
derived from several types of tumours
differing in their clinical radiocurability.
We have also continued our systematic
investigation ofthe in vitroradiosensitivity
ofhuman tumour cell lines.
MATERIALS AND METHODS
With the exception ofmelanomias C-32 and
C-143, the human tumour lines and methods
of establishment and maintenance in culture
have been described in previous publications
(Weichselbaum et al., 1977a, 1980b). In
summary, each line was epithelial in mor-
phology, had gone through at least 100
passages in vitro, and continued to prolifer-
ate after reaching confluence in a manner not
characteristic of normal fibroblasts. Two
tumour lines continued to express certain
characteristics of the in vivo phenotype
(Soule et al., 1973; Weichselbaum et al.,
1980b). MCF-7 (a carcinoma ofthe breast) had
functional steroid receptors, and LAN-1 (a
neuroblastoma) typically showed neuronal
processes extended from cell bodies. The
melanomas C-32 and C-143, which have not
been described in our previous publications,
have been characterized extensively (Chen &
Shaw, 1973; Chen 1978); they were kindly
provided by Dr T. R. Chen. These lines are
heteroploid and easily distinguishable from
normal fibroblasts by morphology. The osteo-
sarcoma lines also all showed a characteristic
morphology in vitro (Weichselbaum et al.,
1977a). No experiments involving HeLa cells
have been carried out in our laboratory for 7
years, and it is unlikely that any of these
human tumour lines became contaminated
with HeLa aftertheyentered our laboratories.
The cells are grown in Eagle's minimal
essential medium (MEM) supplemented with
10% foetal calf serum, 90 mg/l glucose, 0-6
mg/l sodium pyruvate and 15 tg gentamyicin
in an atmosphere of 95% air and 5% Co2.
Irradiations are carried out with a 220 kV
G. E. Maximar unit operating at 15 mA and
yielding a dose rate of 0-8 Gy/min.
Potentially lethaldamage recovery (PLDR)
is measured in density-inhibited plateau-
phase cultures exposed to a single dose of
X-rays. It is defined as the enhancement in
survival when subculture of the cells at low
density was delayed for several hours after
irradiation. The protocol for the measurement
of PLDR is as follows: Cells are plated into
60mm dishes and grown to confluency. Cul-
ture medium is renewed for 3 days and the
experiment performed on the 4th. Cells are
irradiated at room temperature and returned
to the incubator. Single plates are removed
and cells trypsinized and replated at low
density at regular intervals. Medium is
changed 5-7 days after irradiation, and 12-18
days later dishes are rinsed, fixed and stained.
Only colonies observed under a dissecting
microscope to be composed of50 cells or more
are scored as survivors. Results are plotted as
recovery ratio vs time of explant; the
enhancement of survival after subculture is
interpreted as being due to X-ray PLDR. The
recovery ratio (R/Ro) is determined by
dividing the surviving fraction at each time
(R) by the zero-hour survival Ro. R/Ro is
used in order to normalize the data from all
experiments because of variability in the
initial zero-hour survival fraction (S/So). It is
the number of colonies counted after irradia-
tion divided by the number of colonies in
unirradiated cultures. The doses (5-7 Gy)
were designed to yield as nearly as possible
the same forthedifferenttumourlines (Table).
We define sublethal damage repair in
exponentially growing cells as the increase in
survival when a dose ofradiation is split with
an interval ofseveral hours between fractions,
as compared to the survival when the same
total dose is given as a single exposure. The
SLDR is predicted by the extrapolation
number (n) of the single-dose survival curve.
It is measured as follows. Cells are plated and
ascertained to be in exponential growth. An
X-ray dose (2.5-5 Gy) is selected to obtain a
surviving fraction between 0 05 and 0-1. This
dose is divided in half and separated by fixed
intervals oftime from 0 to 10 h and survivors
scored as previously described. Results are
graphed as recovery ratio vs hours between
doses. The enhancement in survival is inter-
preted as being due to SLDR.
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The X-ray survival analysis of the mela-
noma lines C-32 and C-143 was carried out by
the methods previously described (Weichsel-
baum et at., 1977b, 1980a, b) and is as follows.
Cells are maintained as stated above. Expo-
nentially growing cultures were treated with
0 25% trypsin in Mg- and Ca-free Earle's
balanced salt solution. The dissociated cells
were counted in a haemacytometer and
plated at low density in 60mm Falcon culture
dishes. Cells were irradiated 18 h later: By
this time no cell division had yet occurred,
and the cells were present singly on the
dishes (cell multiplicity= 1). Dishes were
returned to the incubator and fixed and
stained as above. Each survival curve rep-
resents a least-square regression analysis of
points from 3 or more experiments. Cloning
efficiencies ranged from 4f6 to 6.9%. Cloning
efficiencyhas beenshown not to correlate with
radiosensitivity (Weichselbaum et al., 1980a,
b; Shipley et al., 1975). The X-ray survival
parameters are the Do or radiosensitivity,
which is the inverse slope of the straight-line
portion of the X-ray survival curve, and the
extrapolation number (n), the back extra-
polation ofthe slope to the ordinate.
RESULTS
PLDR was studied by measuring sur-
vival as a function of time between X-
irradiation of density-inhibited plateau-
phase cultures and their subculture at low
density to measure colony-forming ability.
Various parameters for each tumour line,
including the 24h recovery ratio, the radia-
tion dose and the zero-time survival, are
presented in the Table. The complete,
normalized PLDR curves for each tumour
line are plotted in the charts.
The results for cell lines C-32 and C-143
(melanomas) and TX-4 (osteosarcoma)
irradiated with 7 Gy are shown in Fig. 1.
Recovery ratio is shown on the ordinate,
and the interval between irradiation and
subculture on the abscissa. The results are
pooled from 3 or more separate experi-
ments and normalized to the same initial
survival level. The enhancement seen in
survival reflects the X-ray PLDR.
The X-ray PLDR with cell lines GBM
(glioblastoma), SaOS (osteosarcoma) and
PAS (hypernephroma) is shown in Fig. 2.
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FIG. 1.-PLDR following X-irradiation in 3
human tumour lines 0: melanoma cell line
C-32. (Dose 7 Gy; PE 4-6 6-9%). A: mela-
noma cell line C-143. (Dose was 7 Gy; PE
4 8-29.4%). 0: osteosarcoma cell line
TX-4. (Dose 7 Gy; PE 3-1-9-8%).
The recovery ratios for these tumour lines
varied from 2-5 to 4-4. PAS shows 4-4-fold
recovery at 6 h and 3-fold at 24 h. Each
point represents at least 3 experiments.
Fig. 3 shows PLDR in tumour lines
MCF-7 and MDA (breast cancer) and
LAN-1 (neuroblastoma). These types of
tumour are generally considered radio-
curable. As can be seen in Fig. 3, PLDR
in those lines is less than in the other
tumour lines examined. A large standard
error was observed at the 8 h PLDR point
in LAN-1. Line MDA showed a repro-
ducible decrease in survival at 24 h; 8 and
24 h points are shown in the Table. Again,
each point represents at least 3 experi-
ments.
Because PLDR might be related to the
proliferative activity which occurs in
density-inhibited cultures, and therefore
to the fraction of cells in G1, continuous-
labelling studies were carried out with the
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TABLE.-Summary ofradiobiological and cellular parameters of human tumour lines
Cell line
TX-4
Osteosarcoma
C-143
Melanoma
C-32
Melanoma
MCF-7
Breast carcinoma
MDA-MB 231
Breast carcinoma
SaOS
Osteosarcoma
PAS
Hypernephroma
GBM
Glioblastoma
LAN-1
Neuiroblastoma
Do and n
(Gy)
1-45 1-8
PE
(%)
3-1-9-8
1-51 1-3 4-8-29-4
2-11 1-7 4-6-6-9
1-34 1-3 2-0-20-4
1-35 1-2 51.0-85-4
1-35 2-2 5-8-16-7
1-31 1-2 33-0
1-43 1-4 13-6-14-1
S/So R/Ro
(%) 24h
0-5 24-0
2-6 11-5
4-7 8-2 7
2-3 1-5 5
3-5 8h: 2-0
24h: 1-0
1-2 2-8
1-8 6h: 4-4
24h: 3-0
1-3 2-8
1-49 1-2 2-4-36-8 5-2 1-6 5
N
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FIG. 2.-PLDR following X-irradiation in 3
human tumour lines. PAS (@), a hyper-
nephroma with PE of 33.0%. (Dose 5 Gy.)
SaOS (0), an osteosarcoma with PE 5-8-
16-7%. (Dose 5 Gy.) GBM (-), a glio-
blastoma with 13-6-14-1%. (Dose 7 Gy.)
TX-4 and MCF-7 lines. The percent
labelled cells after 8 h incubation with
[3H]dT as measured by autoradiography
was 28% and 33%, respectively. Thus
there are no obvious differences in the
proliferative activity in plateau cultures
between the 2 lines which showed the
greatest differences in PLDR.
Representative split-dose experiments
T/ME OF POTENT/ALLY LETH/AL DAMAGEREPAIR
(h)
FIG. 3 :-PLDR following X-irradiation in 3
human tumour lines MCF-7 (0) breast
carcinoma. (Dose 5 Gy.) PE 2-0-20-4%.
MDA-MB 231 (A*) breast carcinoma. (Dose
53y.) PE 51-0-85-4%. LAN-i (0) neuro-
blastoma. (Dose 5 Gy.) PE 2-4-36-8%.
with exponentially growing cells are
shown in Figs 4 & 5. These experiments
measure the capacity of the cells to
recover from sublethal damage (SLDR).
The enhancement in survival observed
with MCF-7 and LAN-i, derived from
radiocurable tumours, is similar to that
seen with cells from non-radiocurable
tumours 0-143 and TX-4. The recovery
between doses is predicted by the extra-
Dose
Gy
7
7
5
5
5
7
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FIG. 4.-Repair of sublethal damage (SLDR)
in human tumour lines MCF-7 (0), a breast
carcinoma, and LAN-1 (O), a neuroblas-
toma. Single dose 6 Gy. Dose split at other
intervals, 3+ 3 Gy.
polation numbers, and there is no differ-
ence in SLDR among the tumour lines,
regardless of radiocurability. Recovery
ratio isplotted against time between doses.
Variation in survival with time is due to
progression of cells through the cell cycle.
Each data point represents at least 3
experiments.
The Table shows the DO,n, plating
efficiencies (PE), initial mean surviving
fraction -S/S, and surviving fraction
after 24 h repair (R/Ro), as well as the
dose in each experiment. As can be seen
in the Table, PLDR appears unrelated to
Do or PE. This was true both between
individual experiments and among cell
lines. The initial S/So fractions are gen-
erally similar, with the exception.of cell
line TX-4, which is lower than the others.
Melanoma line C-32 is significantly more
radioresistant (Do = 2 11) than other
tumour lines here examined.
10.0
0 2 4 6 8
TIME BETWEEN DOSES(h)
FIG. 5. SLDR in human tumour lines TX-4
(0), an osteosarcoma, and C-143 (0), a
melanoma. Single dose 8 Gy. Dose split
at other intervals, 4+4 Gy.
DISCUSSION
The curability of malignant tumours
may be related both to local control and
to the development of metastatic disease.
In the tumours described here, we define
radiocurability in terms of the ease of
local control. On this basis, cells from 3
human tumours considered not clinically
radiocurable (2 melanomas and 1 osteo-
sarcoma) demonstrated more PLDR than
all the other lines examined in our study
(24h recovery ratios ranging from 8 to 20).
Three cell lines derived from tumours
considered locally radiocurable (2 breast
and 1 neuroblastoma) showed least PLDR
(24h recovery ratios 1-5-2-0). The other
tumour lines, derived from tumours which
are also generally considered relatively
radioincurable locally, were intermediate
in their capacity for X-ray PLDR.
Normal diploid fibroblast lines show
3-4-fold PLDR at similar survival levels
(Weichselbaum et al., 1978).
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We have demonstrated previously that
significant and measurable PLDR takes
place in human tumour cells exposed to
X-ray doses analogous to the daily doses
used in clinical radiotherapy (Weichsel-
baum et al., 1977b). Therefore, even a 3-4-
fold recovery over a 30-fraction treatment
might cause enough enhancement in the
ultimate surviving fraction to decrease
significantly the local radiocurability of a
particular human tumour. Based on our
data, tumours which are not radiocurable
might be more likely to contain cells
efficient for PLDR. The extent to which in
vivo tumours contain cells analogous to
density-inhibited cells in vitro will bear
direct relevance for PLD in human tumour
radiotherapy. It is difficult to determine
the exact relationship between the cap-
acity of cloned tumour cells in vitro for
PLDR and the capacity of their parent
tumours for PLDR in 8itu. Caution must
be exercised in the interpretation of any
in vitro data in an in vivo situation.
Continuous-labelling studies did not
indicate a higher fraction of G1 cells in
the tumour line (TX-4) with the greatest
PLDR capacity than in the human breast
carcinoma cells (MCF-7), which showed
the lowest capacity for PLDR. This
observation is important, since plateau-
phase cultures with a large G1 population
might be expected to demonstrate more
PLDR than cultures in which the cells
were more actively proliferating, as Little
& Hahn (1973) demonstrated PLDR to
take place primarily in the G1 phase ofthe
cell cycle. Unlike normal human diploid
cells, significant poliferation occurs in
plateau-phase human tumour-cell cultures,
as has been demonstrated in other estab-
lished cell lines. Our results indicate much
less PLDR in MCF-7 cells than in osteo-
sarcoma (TX-4), though on a kinetic
basis a similar PLDR capacity would have
been predicted from similar G, proportion.
We therefore suggest that the capacity
for PLDR is a cellular repair characteristic
which may differ between cell types. This
conclusion is supported by our previous
studies with cells derived from patients
2
with ataxia telangiectasia and xeroderma
pigmentosum (Weichselbaum et al., 1978).
Experiments performed to examine
sublethal damage repair (SLDR) in ex-
ponentially growing cultures of human
malignant tumour cells demonstrated no
significant differences in their capacity for
split-dose recovery, and confirmed that
the amount of SLDR may be predicted
from the extrapolation number. Although
there are no differences between tumours
of varying curability in their ability for
SLDR, the importance ofthis phenomenon
should not be completely discounted,
since all lines examined showed some
SLDR, and the ultimate surviving frac-
tion (thus radiocurability) may depend
upon combinations of SLDR and PLDR.
We have previously reported that the
intrinsic radiosensitivities of a number of
human tumour lines, as measured by
survival-curve parameters, were very
similar (Weichselbaum et al., 1980b). The
human melanoma line C-32, however, is
significantly moreradioresistantthanother
tumour lines we have examined. Other
investigators have reported some human
glioblastoma lines to be radioresistant in
vitro, though the frequency of radio-
resistant cells in vivo is unknown (Gerwick
et al., 1977; Nilsson et al., 1980). Inherent
cellular radioresistance may thus, in some
cases, be an important factor in clinical
radiocurability, though results from sev-
eral laboratories with a wide variety of
human tumour lines have shown few
apart from the C-32 melanoma, to be
unusually radioresistant in vitro (Smith et
al., 1978; Weininger et al., 1978; Wells et
al., 1977).
As has been shown previously (Weich-
selbaum etal., 1977b; Hahn & Little, 1972),
PLDR generally reflects a change in the
slope of the survival curve. For example,
osteosarcoma line TX-4 has a Do of 145
in exponential growth, but of 2-01 after
6h repair time (Weichselbaum et al.,
1977b).
Radiocurability is likely to be a highly
complex function, and variables other
than those discussed here (e.g. hypoxia)
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will no doubt also be of importance under
certain clinical circumstances. We con-
clude however that the repair of poten-
tially lethal X-ray damage may be a major
cellular determinant in human tumour
radiocurability.
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